Published in Mol Ther on August 01, 2004
In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci U S A (2008) 1.48
Postintegrative gene silencing within the Sleeping Beauty transposition system. Mol Cell Biol (2007) 1.15
Quantification of lentiviral vector copy numbers in individual hematopoietic colony-forming cells shows vector dose-dependent effects on the frequency and level of transduction. Gene Ther (2010) 1.14
The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS One (2009) 1.07
Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation in vivo. Mol Ther (2012) 1.05
Erythroid-specific expression of beta-globin by the sleeping beauty transposon for Sickle cell disease. Biochemistry (2007) 0.92
Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency. PLoS One (2012) 0.87
Highly efficient generation of transgenic sheep by lentivirus accompanying the alteration of methylation status. PLoS One (2013) 0.81
Supplying clotting factors from hematopoietic stem cell-derived erythroid and megakaryocytic lineage cells. Mol Ther (2009) 0.79
Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys (2002) 5.16
IMRT commissioning: multiple institution planning and dosimetry comparisons, a report from AAPM Task Group 119. Med Phys (2009) 4.47
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol (2009) 3.99
Guidance document on delivery, treatment planning, and clinical implementation of IMRT: report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee. Med Phys (2003) 3.14
Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med (2012) 2.80
Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2005) 2.35
Low-dose megavoltage cone-beam CT for radiation therapy. Int J Radiat Oncol Biol Phys (2005) 2.33
Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys (2003) 2.29
Lung dose calculation with SPECT/CT for ⁹⁰Yittrium radioembolization of liver cancer. Int J Radiat Oncol Biol Phys (2012) 2.11
Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1 alpha. Blood (2008) 2.09
Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.81
Skin toxicity due to intensity-modulated radiotherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys (2002) 1.76
Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood (2004) 1.74
Implementing IMRT in clinical practice: a joint document of the American Society for Therapeutic Radiology and Oncology and the American Association of Physicists in Medicine. Int J Radiat Oncol Biol Phys (2004) 1.70
Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis. Am J Respir Crit Care Med (2014) 1.53
PON gene polymorphisms and ischaemic stroke: a systematic review and meta analysis. Int J Stroke (2012) 1.49
Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther (2009) 1.46
A triterpene glycoside from black cohosh that inhibits osteoclastogenesis by modulating RANKL and TNFalpha signaling pathways. Chem Biol (2007) 1.44
A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med (2014) 1.42
Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther (2007) 1.40
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment. Genes Dev (2012) 1.40
Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIV-based lentiviral vectors. Blood (2008) 1.37
Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood (2003) 1.37
Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood (2003) 1.35
Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer (2008) 1.31
Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol (2011) 1.30
American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther (2003) 1.29
Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR. Mol Ther (2009) 1.22
High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood (2010) 1.22
Dosimetric evaluation of automatic segmentation for adaptive IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 1.19
Signaling defects in iPSC-derived fragile X premutation neurons. Hum Mol Genet (2012) 1.19
Human progenitor cells with high aldehyde dehydrogenase activity efficiently engraft into damaged liver in a novel model. Hepatology (2009) 1.16
Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT. Med Phys (2008) 1.16
The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets. Int J Radiat Oncol Biol Phys (2002) 1.15
Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential. Cell Stem Cell (2008) 1.15
Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys (2007) 1.15
Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest (2003) 1.11
Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys (2008) 1.11
Guided migration of neural stem cells derived from human embryonic stem cells by an electric field. Stem Cells (2012) 1.11
Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells. Biochem J (2011) 1.09
Investigation of the use of MOSFET for clinical IMRT dosimetric verification. Med Phys (2002) 1.09
The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS One (2009) 1.07
Reversing bone loss by directing mesenchymal stem cells to bone. Stem Cells (2013) 1.06
Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys (2007) 1.05
Unfaithful maintenance of methylation imprints due to loss of maternal nuclear Dnmt1 during somatic cell nuclear transfer. PLoS One (2011) 1.04
Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma. J Neurosurg Spine (2012) 1.03
Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease. Blood (2008) 1.02
Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. FASEB J (2010) 1.01
Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A (2009) 1.00
Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.00
Can all centers plan intensity-modulated radiotherapy (IMRT) effectively? An external audit of dosimetric comparisons between three-dimensional conformal radiotherapy and IMRT for adjuvant chemoradiation for gastric cancer. Int J Radiat Oncol Biol Phys (2008) 0.99
Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood (2013) 0.98
Patient dose considerations for routine megavoltage cone-beam CT imaging. Med Phys (2007) 0.98
Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD). J Biol Chem (2010) 0.98
Pathophysiology and therapy for haemoglobinopathies. Part I: sickle cell disease. Expert Rev Mol Med (2006) 0.98
Can positron emission tomography (PET) or PET/Computed Tomography (CT) acquired in a nontreatment position be accurately registered to a head-and-neck radiotherapy planning CT? Int J Radiat Oncol Biol Phys (2008) 0.98
Human CD34(+) and CD34(+)CD38(-) hematopoietic progenitors in sickle cell disease differ phenotypically and functionally from normal and suggest distinct subpopulations that generate F cells. Exp Hematol (2004) 0.97
Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease. Hum Mol Genet (2009) 0.97
Murine retroviral but not human cellular promoters induce in vivo erythroid-specific deregulation that can be partially prevented by insulators. Mol Ther (2007) 0.95
Method to account for dose fractionation in analysis of IMRT plans: modified equivalent uniform dose. Int J Radiat Oncol Biol Phys (2005) 0.95
Relationship of imaging frequency and planning margin to account for intrafraction prostate motion: analysis based on real-time monitoring data. Int J Radiat Oncol Biol Phys (2012) 0.95
Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II. Hum Mol Genet (2008) 0.95
Dose calculation using megavoltage cone-beam CT. Int J Radiat Oncol Biol Phys (2007) 0.93
A new smoothing procedure to reduce delivery segments for static MLC-based IMRT planning. Med Phys (2004) 0.93
Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes. Int J Radiat Oncol Biol Phys (2011) 0.93
A population-based atlas and clinical target volume for the head-and-neck lymph nodes. Int J Radiat Oncol Biol Phys (2004) 0.93
Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys (2003) 0.93
Biomarkers for early detection of sickle nephropathy. Am J Hematol (2011) 0.92
Role of miRNAs in neuronal differentiation from human embryonic stem cell-derived neural stem cells. Stem Cell Rev (2012) 0.91
[Successful gene therapy of mice with congenital erythropoietic porphyria]. Med Sci (Paris) (2008) 0.90
Molecular characterization of the human NANOG protein. Stem Cells (2009) 0.90
Comparison between hybrid direct aperture optimized intensity-modulated radiotherapy and forward planning intensity-modulated radiotherapy for whole breast irradiation. Int J Radiat Oncol Biol Phys (2010) 0.90
A forward-planned treatment technique using multisegments in the treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys (2004) 0.90
Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13. J Clin Invest (2015) 0.90
Dose calculation differences between Monte Carlo and pencil beam depend on the tumor locations and volumes for lung stereotactic body radiation therapy. J Appl Clin Med Phys (2013) 0.87
Contribution of human hematopoietic stem cells to liver repair. Semin Immunopathol (2009) 0.87
Aberrant expression and methylation status of putatively imprinted genes in placenta of cloned piglets. Cell Reprogram (2010) 0.87
Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency. PLoS One (2012) 0.87
Assessing feasibility of real-time ultrasound monitoring in stereotactic body radiotherapy of liver tumors. Technol Cancer Res Treat (2013) 0.86
Highly efficient lentiviral gene transfer in CD34+ and CD34+/38-/lin- cells from mobilized peripheral blood after cytokine prestimulation. Stem Cells (2003) 0.86
Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 0.86
Sensitivity and specificity of immunocytochemical staining of mycobacterial antigens in the cytoplasm of cerebrospinal fluid macrophages for diagnosing tuberculous meningitis. J Clin Microbiol (2011) 0.86
RhoA GTPase controls cytokinesis and programmed necrosis of hematopoietic progenitors. J Exp Med (2013) 0.85
Tbx3 and Nr5α2 play important roles in pig pluripotent stem cells. Stem Cell Rev (2013) 0.85
The oncogene LRF is a survival factor in chondrosarcoma and contributes to tumor malignancy and drug resistance. Carcinogenesis (2012) 0.84
Detection of treatment setup errors between two CT scans for patients with head and neck cancer. Med Phys (2007) 0.84
Human thymus mesenchymal stromal cells augment force production in self-organized cardiac tissue. Ann Thorac Surg (2010) 0.84
Therapy for beta-globinopathies: a brief review and determinants for successful and safe correction. Ann N Y Acad Sci (2010) 0.84
Germinal vesicle chromatin configurations of bovine oocytes. Microsc Res Tech (2006) 0.83
Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria. Proc Natl Acad Sci U S A (2013) 0.83
Immortalization of murine muscle cells from lysosomal alpha-glucosidase deficient mice: a new tool to study pathophysiology and assess therapeutic strategies for Pompe disease. Biochem Biophys Res Commun (2009) 0.83
Flattening filter-free accelerators: a report from the AAPM Therapy Emerging Technology Assessment Work Group. J Appl Clin Med Phys (2015) 0.83
Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease. J Gene Med (2009) 0.82